Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea & Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights

Source :: Plus Company Updates. January 21, 2023
Publication Year :: 2023
Abstract: EXTON: The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherix's RealWorld Dynamix service takes a unique approach to the typical [...]

Subjects :: Biological products industry -- Product discontinuation
Macular degeneration -- Physiological aspects
Angiogenesis inhibitors -- Physiological aspects
General interest
News, opinion and commentary
Vabysmo (Medication) -- Product discontinuation

Tools